← Back to patent-cliff list
CAS 3132-99-8
(3-Bromophenyl)formaldehyde3-bromobenzaldehyde
Codes: (I)101438-4-a, MONT-028
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelAllergic rhinitisMontelukastAsthmaMontelukastHypersensitivity reactionMontelukastSeasonal allergic rhinitisMontelukastPerennial allergic rhinitisMontelukastExercise-induced asthmaMontelukast
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Montelukast | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3-Bromophenyl)formaldehyde→1-Amino-4-methoxybenzene→(NZ)-N-[(3-bromophenyl)methylidene]-4-methoxyaniline→(2-Chloranyl-2-oxidanylideneethyl) ethanoate→alpha-Chlorobenzaldehyde→(2S,3R)-2-(3-bromophenyl)-1-(4-methoxyphenyl)-4-oxoazetidin-3-yl acetate→(2S,3R)-2-(3-bromophenyl)-4-oxoazetidin-3-yl acetate→(3R,4S)-4-(3-bromophenyl)-3-hydroxyazetidin-2-one→(3R,4S)-4-(3-bromophenyl)-3-[(triethylsilyl)oxy]azetidin-2-one→(3R,4S)-1-benzoyl-4-(3-bromophenyl)-3-[(triethylsilyl)oxy]azetidin-2-one→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,7,13-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-3-(3-bromophenyl)-3-(phenylformamido)-2-[(triethylsilyl)oxy]propanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-3-(3-bromophenyl)-2-hydroxy-3-(phenylformamido)propanoyl]oxy}-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-13-[[(2R,3S)-3-benzamido-2-hydroxy-3-(3-tritiophenylpropanoyl]oxy]-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(3-Bromophenyl)formaldehyde→1-Amino-4-methoxybenzene→(NZ)-N-[(3-bromophenyl)methylidene]-4-methoxyaniline→(2-Chloranyl-2-oxidanylideneethyl) ethanoate→alpha-Chlorobenzaldehyde→(2S,3R)-2-(3-bromophenyl)-1-(4-methoxyphenyl)-4-oxoazetidin-3-yl acetate→(2S,3R)-2-(3-bromophenyl)-4-oxoazetidin-3-yl acetate→(3R,4S)-4-(3-bromophenyl)-3-hydroxyazetidin-2-one→(3R,4S)-4-(3-bromophenyl)-3-[(triethylsilyl)oxy]azetidin-2-one→(3R,4S)-1-benzoyl-4-(3-bromophenyl)-3-[(triethylsilyl)oxy]azetidin-2-one→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,7,13-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-3-(3-bromophenyl)-3-(phenylformamido)-2-[(triethylsilyl)oxy]propanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-3-(3-bromophenyl)-2-hydroxy-3-(phenylformamido)propanoyl]oxy}-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-13-[[(2R,3S)-3-benzamido-2-hydroxy-3-(3-tritiophenylpropanoyl]oxy]-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid→3-bromobenzaldehyde→1-(3-bromophenyl)prop-2-en-1-ol→methyl 2-iodobenzoate→methyl 2-(3-(3-bromophenyl)-3-oxopropyl)benzoate→methyl (S)-2-(3-(3-bromophenyl)-3-hydroxypropyl)benzoate→(S)-1-(3-bromophenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol→2-(1-(mercaptomethyl)cyclopropyl)acetonitrile→(R)-2-(1-(((1-(3-bromophenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetonitrile→7-chloro-2-vinylquinoline→(R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetonitrile→7-chloroquinoline-2-carbaldehyde
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.